Human Neutrophil Peptides sputum levels in symptomatic smokers and COPD patients

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 5, 2011, Pages 556-562

  Paone, G ^a,b   Conti, V ^a   Leone, A ^c   Schmid, G ^b   Puglisi, G ^c   Giannunzio, G ^c   Terzano, Claudio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Airway inflammation; Chronic obstructive pulmonary disease; Human neutrophil peptides; Smoking; Sputum

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE; HUMAN NEUTROPHIL PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG; ALPHA DEFENSIN;

ADULT; AIRWAY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OXYGEN SATURATION; PEPTIDE ANALYSIS; PROTEIN ANALYSIS; SAMPLING; SMOKING CESSATION; SPUTUM ANALYSIS; SPUTUM LEVEL; TRANSCUTANEOUS OXYGEN MONITORING; BLOOD; CHEMISTRY; IMMUNOLOGY; MIDDLE AGED; SMOKING; SPUTUM;

ALPHA-DEFENSINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SMOKING CESSATION; SPUTUM;

EID: 79960975572     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. RABE KF, HURD S, ANZUETO A, BARNES PJ, BUIST SA, CALVERLEY P, FUKUCHI Y, JENKINS C, RODRIGUEZ-ROISIN R, VAN WEEL C, ZIELINSKI J; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
2. KIM V, ROGERS TJ, CRINER GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 478-485.
3. HOGG JC, MACKLEM PT, THURLBECK WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360.
4. YAMAMOTO C, YONEDA T, YOSHIKAWA M, FU A, TOKUYAMA T, TSUKAGUCHI K, NARITA N. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-510.
5. BURROWS B, BLOOM JW, TRAVER GA, CLINE MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
6. HUNNINGHAKE GW, CRYSTAL RG. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lung of cigarette smokers. Am Rev Respir Dis 1983; 128: 833-838.
7. LAUBE DM, YIM S, RYAN LK, KISICH KO, DIAMOND G. Antimicrobial peptides in the air way. Curr Top Microbiol Immunol 2006; 306: 153-182.
8. COLE AM, WARING AJ. The role of defensins in lung biology and therapy. Am J Respir Med 2002; 1: 249-259.
9. SOONG LB, GANZ T, ELLISON A, CAUGHEY GH. Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res 1997; 46: 98-102.
10. SPENCER LT, PAONE G, KREIN PM, ROUHANI FN, RIVERA-NIEVES J, BRANTLY ML. Role of human neutrophil peptides in lung inflammation associated with α1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol 2004; 286: L514-L520.
11. ASHITANI J, MUKAE H, IHIBOSHI H, TANIGUCHI H, MASHIMOTO H, NAKAZATO M, MATSUKURA S. Defensins in plasma and in bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34: 1349-1353.
12. VAN WETERING S, STERK PJ, RABE KF, HIEMSTRA PS. Defensins: key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol 1999; 104: 1131-1138.
13. PAONE G, WADA A, STEVENS LA, MATIN A, HIRAYAMA T, LEVINE RL, MOSS J. ADP ribosylation of human neutrophil peptide-1 regulates its biological properties. Proc Natl Acad Sci USA 2002; 99: 8231-8235.
14. GÓRECKA D, BEDNAREK M, NOWINSKI A, PUSCINSKA E, GOLIAN-GEREMEK A, ZIELINSKI J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.
15. QUANJIER PH, TAMMELING GJ, COTES JE, PEDERSON OF, PESLIN R, YERAULT JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Test, European Community for Steal and Coal. Official Statement of the European Respiratory Society. Eur Resp J Suppl 1993; 6: 5-40.
16. LOUHELAINEN N, STARK H, MAZUR W, RYTILÄ P, DJUKANOVIC R, KINNULA VL. Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study. BMC Pulm Med 2010; 10: 13.
17. LAPPERRE TS, WILLEMS LN, TIMENS W, RABE KF, HIEMSTRA PS, POSTMA DS, STERK PJ. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 2007; 131: 53-59.
18. SADOWSKA AM, VAN OVERVELD FJ, GÓRECKA D, ZDRAL A, FILEWSKA M, DEMKOW UA, LUYTEN C, SAENEN E, ZIELINSKi J, DE BACKER WA. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med 2005; 99: 241-249.
19. WOOLHOUSE IS, BAYLEY DL, STOCKLEY RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha1-antitrypsin deficiency and the role of leukotriene B4 and interleukin 8. Thorax 2002; 57: 709-714.
20. PESCI A, BALBI B, MAJORI M, CACCIANI G, BERTACCO S, ALCIATO P, DONNER CF. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 380-386.
21. WILLEMSE BWM, TEN HACKEN NHT, RUTGERS B, LESMAN-LEEGTE IGAT, POSTMA DS, TIMENS W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26: 835-845.
22. HACIEVLIYAGIL SS, GUNEN H, MUTLU LC, KARABULUT AB, TEMEL I. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006; 100: 846-854.
23. WILLEMSE BW, TEN HACKEN NH, RUTGERS B, POSTMA DS, TIMENS W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res 2005; 6: 38.
24. KEATINGS VM, COLLINS PD, SCOTT DM, BARNES PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
25. ANDELID K, BAKE B, RAK S, LINDÉN A, ROSENGREN A, EKBERG-JANSSON A. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir Med 2007; 101: 888-895.
26. LI QY, HUANG SG, WAN HY, WU HC, ZHOU T, LI M, DENG WW. Effect of smoking cessation on airway inflammation of rats with chronic bronchitis. Chin Med J 2007; 120: 1511-1516.
27. BARCZYK A, SOZAÑSKA E, TRZASKA M, PIERZCHALA W. Decreased levels of myeloperoxidase in induced sputum of patients with COPD after treatment with oral glucocorticoids. Chest 2004; 126: 389-393.
28. TAKANASHI S, HASEGAWA Y, KANEHIRA Y, YAMAMOTO K, FUJIMOTO K, SATOH K, OKAMURA K. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999; 14: 309-314.
29. VERNOOY JHJ, LINDEMAN JHN, JACOBS JA, HANEMAAIJER R, WOUTERS EFM. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126: 1802-1810.
30. BEEH KM, BEIER J, KORNMANN O, BUHL R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97: 634-639.
31. CULPITT SV, ROGERS DF, TRAVES SL, BARNES PJ, DONNELLY LE. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005; 99: 703-710.
32. MERCER PF, SHUTE JK, BHOWMIK A, DONALDSON GC, WEDZICHA JA, WARNER JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 2005; 6: 151.
33. DONALDSON GC, SEEMUNGAL TA, PATEL IS, BHOWMIK A, WILKINSON TM, HURST JR, MACCALLUM PK, WEDZICHA JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
34. GANZ T. Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun 1987; 55: 568-571.
35. OKRENT DG, LICHTENSTEIN AK, GANZ T. Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells. Am Rev Respir Dis 1990; 141: 179-185.
36. PANYUTICH AV, HIEMSTRA PS, VAN WETERING S, GANZ T. Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol 1995; 12: 351-357.
37. VIGNOLA AM, BONANNO A, MIRABELLA A, RICCOBONO L, MIRABELLA F, PROFITA M, BELLIA V, BOUSQUET J, BONSIGNORE G. Increased levels of elastase and alpha1-antitrypsin in sputum of asthmatic patients. Am J Respir Crit Care Med 1998; 157: 505-511.